Healthy
Conditions
Brief summary
This study will assess the systemic exposure and pharmacokinetic parameters of SP-103 topical system following one, two, or three topical system applications and compare to the pharmacokinetics of ZTlido.
Interventions
DRUGSP-103
lidocaine topical system 5.4%
DRUGZTlido
lidocaine topical system 1.8%
Sponsors
Scilex Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
Key Inclusion Criteria: * Must be healthy based on by medical history, laboratory work, ECG, and physical exam * Body mass index ranging between 18.0-32.5 kg/m2, inclusive * If childbearing potential, use of acceptable form of birth control * In the case of females of childbearing potential, have a negative serum pregnancy test Key
Exclusion criteria
* Allergy or known hypersensitivity to lidocaine, amide-type local anesthetics or any component of the product formulation * Any major medical illness 3 months prior or any significant history or ongoing chronic medical illness affecting the major body systems, including the skin * Subjects with conditions that might affect application of the product or its adhesive properties (including psoriasis, eczema, atopic dermatitis, damaged or irritated epidermal layer, and excessive hair or oil on the skin) * Use of antiarrhymthic drugs (such as tocainide and mexiletine) and local anesthetics within 14 days prior to product application. * History of addiction, abuse, or misuse of any drug * Use of nicotine-containing products within 30 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Peak plasma concentration (Cmax) of lidocaine | 0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose | Peak plasma concentration of lidocaine after 12 hour topical system application |
| Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time 48 hours | 0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose | Area under the plasma concentration versus time curve from 0 to 48 hours of lidocaine in plasma |
| Area under the Plasma-Concentration Time Curve (AUC) from Time 0 to Time Infinity | 0, 2, 4, 6, 9, 10, 11, 12, 13, 14, 16, 18, 20, 22, 24, 48 hours post-dose | Area under the plasma concentration versus time curve from 0 to infinite time of lidocaine in plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean adhesion score | 0, 3, 6, 9, 12 hours post-dose | Adhesion to skin assessed by FDA 0-4 scoring system. The scoring for adhesion of patches is indicated as follows: 0 = ≥ 90% Adhered (essentially no lift off the skin), 1 = ≥ 75% to \< 90% Adhered (some edges only lifting off the skin), 2 = ≥ 50% to \< 75% Adhered (less than half of the patch lifting off the skin), \> 0% to \< 50% Adhered but not detached (more than half of the patch lifting off the skin without falling off), and 4 = 0% adhered (patched completely detached). The mean score is calculated as the average of scores at time 3, 6, 9, and 12 hours. |
| Dermal response score | 12.5 and 14 hours post-dose | Product tolerability is assessed by Dermal Response Score. The application site is evaluated 30 minutes and 2 hours after product removal (12.5 and 14 hours post-dose, respectively). Response score from 0 to 7; 0= No evidence of irritation, 1= Minimal erythema, barely perceptible, 2= Definite erythema, readily visible; minimal edema or minimal papular response, 3= Erythema and papules, 4= Definite edema, 5= Erythema, edema and papules, 6= Vesicular eruption, 7= Strong reaction spreading beyond test (i.e., application) site. |
Countries
United States
Outcome results
None listed